Secondary prevention and cardiac rehabilitation in Spain;Prevencion secundaria y rehabilitacion cardiaca en Espana

Revista Espanola de Cardiologia

Volumn 49, Issue 8, 1996, Pages 549-553

  Pérez, Ignacio Plaza ^a   Rami, José Antonio Velasco ^b   Montero, José María Maroto ^c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

cardiac rehabilitation; coronary heart disease; hypercholesterolaemia; secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

COST BENEFIT ANALYSIS; HEART REHABILITATION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MORTALITY; SECONDARY PREVENTION; SHORT SURVEY; SPAIN; ARTICLE; HEART MUSCLE ISCHEMIA; PUBLIC HEALTH;

COST-BENEFIT ANALYSIS; HUMANS; MYOCARDIAL ISCHEMIA; PUBLIC HEALTH; SPAIN;

EID: 0030211155     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (25)

1. WHO Regional Office for Europe. Needs and action priorities in cardiac rehabilitation and secondary prevention in patients with coronary artery disease. Report on two WHO Consultations, EUR/HFA Target 9. Copenhague, 1993.
2. Plaza I. Epidemiología y preventión primaria de la cardiopatía isquémica. Rev Esp Cardiol 1987; 41: 35-55.
3. Carmena R, Plaza I. Smoking and nutrition in Spanish adolescents. Nutr Metab Cardiovasc Dis 1991; 1: 115-116.
4. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1.383-1.389.
5. Rossouw J, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990; 323: 1.112-1.119
6. Carleton RA, Dwyer J, Finberg L, Flora J, Goddman DS, Grundy SM et al. Report of the expert panel on population stategies for blood cholesterol reduction. A statement from the National Cholesterol Education Program, NHLBI, NIH. Circulation 1991; 83: 2. 154-2.232.
7. Pekkanen J, Linn S, Heiss G, Suchindran Ch M, Leon A, Rifkind BM et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1.700-1.707.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3.015-3.023.
9. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-373.
10. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet treatment I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients Br Med J 1994; 308: 81-106.
11. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet treatment. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994; 308: 159-168.
12. American Association of Cardiovascular and Pulmonary Rehabilitation. Guidelines for cardiac rehabilitation programs. Human Kinetics, 1994.
13. Fletcher BJ, Thiel J, Fletcher GF, Phase II intensive monitored cardiac rehabilitation for coronary artery disease and coronary risk factors: A six-session protocol. Am J Cardiol 1986; 56: 751-756.
14. Maroto JM, De Pablo C, Artigao R, Morales MD, Lozano M, Carcedo C et al. Rehabilitación en la cardiopatía isquémica. Resultados a nivel de calidad de vida y sobre el pronóstico. Arch Inst Cardiol Méx 1992; 62: 441-446.
15. Maroto JM, Artigao R, Morales M, Ridoci Tormo V, Velasco JA. Rehabilitación cardíaca: Recomendaciones sobre necesidades, recursos técnicos y humanos. Libro de procedimientos de la Sociedad Espanola de Cardiología. Madrid, 1991; 15-17.
16. Velasco JA, Maureira JJ. Rehabilitación del paciente cardíaco Barcelona: Ed. Doyma, 1993.
17. Velasco JA. Objetivos de la rehabilitación cardíaca. Estado actual y perspectivas futuras. En: Velasco JA, Maureira JJ, editores. Rehabilitación del paciente cardíaco. Barcelona: Ed. Doyma, 1993; 1-9.
18. Oldridge NB, Guyatt GH, Fisher ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomised clinical trials. JAMA 1988; 260: 945-950.
19. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS et al. An overview of randomised trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234-244.
20. Velasco JA Return to work issues as a component of cardiac rehabilitation. Biblthca Cardiol 1986; 40: 94-108.
21. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an owerview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-351.
22. Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 1992; 2: 113-156.
23. Multiple Risk Factor Intervention Trial Research Group. MRFIT risk factors changes and mortality results. JAMA 1982; 248: 1.465-1.477.
24. Sobrino JA, Merino JL, Maté I, García García J, Rico J, Plaza I et al. Retorno al trabajo después de la revascularización coronaria. Rev Esp Cardiol 1995; 48: 183-186.
25. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1.300-1.331.